Diagnostic soluble fragment of triggering receptor expressed on myeloid cells 2 (sTREM2) antibodies (anti-soluble fragment of triggering receptor expressed on myeloid cells 2, anti-sTREM2) and antigens (recombinant soluble fragment of triggering receptor expressed on myeloid cells 2 (sTREM2) protein) for Neurodegenerative diseases sTREM2 detection in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT.
Cat:GMP-h-sTREM2
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Genemedi produces core diagnostic ingredients for test of Neurodegenerative diseases (Alzheimer Disease(AD)) and related syndrome. GeneMedi offers paired diagnostics grade soluble fragment of triggering receptor expressed on myeloid cells 2 (sTREM2) antibodies (monoclonal antibody, mab) and antigens for Neurodegenerative diseases (Alzheimer Disease(AD)) rapid test kit of soluble fragment of triggering receptor expressed on myeloid cells 2 (sTREM2) testing in standard substance, positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT. All the antibodies and antigens for Neurodegenerative diseases (Alzheimer Disease(AD) ) test are suitable for in functional ELISA, and other immunoassays in dignostics.The antibodies can act as a capture antibody and detection antibody. The antigens can be used as positive control.
Genemedi produces core diagnostic ingredients for test of Neurodegenerative diseases (Alzheimer Disease(AD)) and related syndrome. GeneMedi offers paired diagnostics grade soluble fragment of triggering receptor expressed on myeloid cells 2 (sTREM2) antibodies (monoclonal antibody, mab) and antigens for Neurodegenerative diseases (Alzheimer Disease(AD)) rapid test kit of soluble fragment of triggering receptor expressed on myeloid cells 2 (sTREM2) testing in standard substance, positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT. All the antibodies and antigens for Neurodegenerative diseases (Alzheimer Disease(AD) ) test are suitable for in functional ELISA, and other immunoassays in dignostics.The antibodies can act as a capture antibody and detection antibody. The antigens can be used as positive control.TREM2 is a microglial transmembrane protein that is proteolytically processed to release a soluble fragment (sTREM2). Meta-analysis of available data finds sTREM2 levels are somewhat higher in people with AD than in controls (effect size = 1.314, p <0.0001).
Product Description
Cat No. of Pruducts
GMP-h-sTREM2-Ag01
Product Name
Recombinant human Human sTREM2 Protein
Target
soluble fragment of triggering receptor expressed on myeloid cells 2
Alias of Target/Biomarker
Expression platform
E.coli
Isotypes
Recombinant Antigen
Bioactivity validation
soluble fragment of triggering receptor expressed on myeloid cells 2 (sTREM2) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in sTREM2 level test of Neurodegenerative diseases (Alzheimer Disease(AD)) and related syndrome evaluation
Tag
His
Products description
Recombinant human Human sTREM2 Protein was expressed in E.coli -based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Reconized/Reactive Species
Human
Purity
Purity: ≥95% (SDS-PAGE)
Application
positive control,
ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
Formulation
Supplied as a 0.2 μM filtered solution of PBS,PH7.4.
Storage
Store at -20℃ to -112℃ under sterile conditions. Avoid repeated freeze-thaw cycles.
Previous slide
Next slide
Cat No. of Pruducts
GMP-h-sTREM2-Ab01,GMP-h-sTREM2-Ab02
Product Name
Anti-human Human sTREM2 mouse monoclonal antibody (mAb)
Target
soluble fragment of triggering receptor expressed on myeloid cells 2
Alias of Target/Biomarker
PLOSL2, TREM-2, Trem2a, Trem2b, Trem2c
Expression platform
Hybridoma
Isotypes
Mouse IgG
Bioactivity validation
Human soluble fragment of triggering receptor expressed on myeloid cells 2 (sTREM2) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other soluble fragment of triggering receptor expressed on myeloid cells 2 (sTREM2) antibodies in sTREM2 level test of Neurodegenerative diseases (Alzheimer Disease(AD)) and related syndrome evaluation.
Tag
mFc
Products description
Anti-human Human sTREM2 mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by hybridoma technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other soluble fragment of triggering receptor expressed on myeloid cells 2 (sTREM2) antibodies.
Reconized/Reactive Species
Human
Purity
Purity: ≥95% (SDS-PAGE)
Application
ELISA test, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT
Formulation
Supplied as a 0.2 μM filtered solution of PBS,PH7.4.
Storage
Store at -20℃ to -113℃ under sterile conditions. Avoid repeated freeze-thaw cycles.
Diagnostic antibodies and antigens for cancer detection - TG, CA-125, SCC Ag, PIVKA-Ⅱ, ProGRP, Calcitonin, NSE, CA-724, HE4, CA15-3, FER, CYFRA21-1, HER2, HSP90α, S100B, CEA, AFP, sFlt-1, PSA, hEGF, TFF2, TFF3, CA199, CA50, TK1
Regardless of the advances in the cancer therapy, delayed symptoms and lack of successful diagnosis of cancer at early stage increased the death rate. Tumor-associated antigens (TAAs) and their antibodies have been identified as potential markers in cancer diagnosis and determination. TAAs and their antibodies-based detection of cancer have the advantages such as low-cost, and simple access, which attracted much attention for early cancer detection. For several reasons, tumor marker itself is typically insufficient to analyze disease conditions. Because, maximum number of markers have been produced by both normal and cancer cells. Several cancers such as anal, breast, ovaries, testicles, colon, endometrial, peritoneal, fallopian tube, gallbladder, gastric, liver, lung, neuroendocrine, pancreatic, prostate, renal, cervix, stomach and thyroid cancer, bronchopulmonary dysplasia, hepatitis, hematological malignancies, hemochromatosis, hypercalcemia, osteoporosis, Parget’s diseases and so on have been identified using specific marker. Detecting the quantity of marker proteins from different samples may benefit from ELISA, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT.
